Nighttime administration of high-dose, sustained-release melatonin does not decrease nocturnal blood pressure in African-American patients: Results from a preliminary randomized, crossover trial.

Abstract

OBJECTIVES\nThis preliminary study tested whether a high-dose, sustained-release form of melatonin reduced 24-hour blood pressure in African-Americans.\n\n\nDESIGN\nRandomized, placebo-controlled, crossover pilot study of 40 self-defined African-American patients with essential hypertension.\n\n\nSETTINGS/LOCATION\nUrban, academic medical center and associated outpatient clinics.\n\n\nINTERVENTIONS\nPatients ingested either melatonin (high dose [24\u2009mg], sustained-release formulation] or placebo in randomized order over a 4-week period.\n\n\nOUTCOME MEASURES\nMean nighttime and daytime systolic and diastolic blood pressures, as measured with 24-hour ambulatory blood pressure monitors. The primary outcome was mean nighttime systolic blood pressure.\n\n\nRESULTS\nThere were no statistically differences between melatonin and placebo conditions in mean nighttime or daytime systolic or diastolic blood pressures.\n\n\nCONCLUSIONS\nIn contrast with studies in other populations, this preliminary study showed that nighttime dosing of continuous-release melatonin had no significant effect on nocturnal blood pressure in African Americans with essential hypertension when compared to placebo.